Ko Kim, NP
Nurse Practitioner · Chapel Hill, NCNPI 1811668841
Payments from drug & device makers
Across 331 payments — averaging $25.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Scilex Pharmaceuticals Inc.$1K
- Livanova USA, Inc.$847
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$694
- Forte Bio-pharma LLC$547
- Si-bone, Inc.$537
- Axsome Therapeutics, Inc.$496
- plus $4K from 28 others
What the payments were for
- Travel & lodging$1,01112%
- Food & beverage$7,25087%
- Education$431%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Scilex Pharmaceuticals Inc. | 65 | $1,120 |
| Livanova USA, Inc. | 4 | $847 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 35 | $694 |
| Forte Bio-pharma LLC | 27 | $547 |
| Si-bone, Inc. | 2 | $537 |
| Axsome Therapeutics, Inc. | 15 | $496 |
| Nevro Corp. | 9 | $462 |
| Valinor Pharma, LLC | 19 | $373 |
| Globus Medical | 8 | $368 |
| AbbVie | 20 | $335 |
| Novartis | 22 | $331 |
| Jazz Pharmaceuticals Inc. | 18 | $316 |
| Neurelis, Inc. | 10 | $304 |
| Collegium Pharmaceutical, Inc. | 12 | $265 |
| Neurocrine Biosciences, Inc. | 13 | $183 |
| UCB, Inc. | 7 | $171 |
| Eisai Inc. | 5 | $165 |
| Lundbeck LLC | 5 | $103 |
| Pfizer | 6 | $94 |
| Inspire Medical Systems, Inc. | 4 | $86 |
| SK Life Science, Inc. | 3 | $79 |
| Virtus Pharmaceuticals LLC | 3 | $73 |
| Teva Pharmaceuticals USA, Inc. | 3 | $56 |
| Vertex | 2 | $49 |
| Lilly USA, LLC | 3 | $41 |
| TG Therapeutics, Inc. | 1 | $34 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $31 |
| Azurity Pharmaceuticals, Inc. | 2 | $29 |
| Harmony Biosciences LLC | 1 | $24 |
| AstraZeneca | 1 | $24 |
| GRT US Holding, Inc. | 1 | $22 |
| Avion Pharmaceuticals | 1 | $19 |
| Medtronic | 1 | $14 |
| USWM, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$847
- IFUSE IMPLANT SYSTEM$522
- Senza$409
- VALTOCO$125
- Leqembi$122
- SUNOSI$122
How this compares
$8,304 in reported general payments places this provider in the 95th percentile of 4,393 nurse practitioner providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 387 | $167,012 |
| RelistorMethylnaltrexone Bromide | 39 | $106,781 |
| ZtlidoLidocaine | 85 | $83,015 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 1,033 | $41,793 |
| Nurtec OdtRimegepant Sulfate | 35 | $39,461 |
| Buprenorphine | 158 | $36,552 |
| LinzessLinaclotide | 56 | $36,129 |
| OxycontinOxycodone Hcl | 75 | $35,918 |
| BelbucaBuprenorphine Hcl | 60 | $32,120 |
| Nucynta ErTapentadol Hcl | 50 | $30,107 |
| HorizantGabapentin Enacarbil | 32 | $28,364 |
| QuliptaAtogepant | 22 | $23,636 |
| Aimovig AutoinjectorErenumab-Aooe | 23 | $23,152 |
| UbrelvyUbrogepant | 15 | $18,407 |
| MovantikNaloxegol Oxalate | 34 | $15,645 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca, Nucynta Er, Nucynta | $265 | $239,680512 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $694 | $106,78139 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $1,120 | $83,01585 claims |
| AbbVieLinzess, Qulipta, Ubrelvy | $335 | $78,17293 claims |
| PfizerNurtec Odt | $94 | $39,46135 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,393 nurse practitioner providers in North Carolina.
Other nurse practitioner in Chapel Hill
- Deborah MayerChapel Hill$55K
- Sarah WatersChapel Hill$29K
- Sandrivette JohnsonRaleigh$573K
- Skyler RogersPinehurst$174K
- Jamie DinerDurham$170K
- Ayeshia WrightMocksville$145K
- Deborah AllenDurham$112K
- Jeanann VawterGastonia$97K
- Terra KampJacksonville$72K
- Mary DilorenzoCharlotte$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.